Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: GERBER who wrote (73628)	5/5/1999 11:58:00 PM
From: Witold	Read Replies (1) \| Respond to of 119973

Tokyo: CYTO, a biotech company, conference call is tomorrow live on the Internet. CYTO has good products: pain killers for certain types of cancer. In the past, they failed to market their products and their stock has suffered severe losses for quite some time; now it is around the baseline value of $1. CYTO has made changes in their management and, IMO, they will be able to increase their revenues soon (there is a good market for their approved products, they just need to advertise it well, sell and make$$$$.... Their products are approved in US and Canada). Recently CYTO has been using a direct marketing strategy to doctors, hospitals. ***** NEW YORK, May 5 /PRNewswire/ -- In conjunction with Cytogen Corporation's (Nasdaq: CYTO - news) First Quarter earnings press release, you are invited to listen to its conference call that will be broadcast live over the Internet on Thursday, May 6 at 11:00 AM, EDT, with Dr. H. Joseph Reiser, President and Chief Executive Officer of Cytogen Corporation. What: Cytogen Corporation's First Quarter Earnings Release When: Thursday, May 6 at 11:00 AM, EDT Where: videonewswire.com How: Live over the Internet -- Simply log on to the web at the address above Contact: Anjani Shah, Noonan Russo Communications, 212-696-4455, ext. 340 Cytogen Corporation, based in Princeton, New Jersey, is a biopharmaceutical company engaged in the development and commercialization of products for the targeted delivery of diagnostic and therapeutic substances directly to disease sites. Cytogen has three products on the market including ProstaScint®, a prostate cancer diagnostic, Quadramet®, a treatment of bone cancer pain and OncoScint®, an imaging agent for colorectal and ovarian cancers. Cytogen also holds the intellectual property rights to PSMA (Prostrate Specific Membrane Antigen), a protein marker under development for immunotherapeutic approaches, particularly in the area of prostrate cancer... **********